AGP Executive Report
Last update: 10 hours agoSynthetic CBD Approval: Leiutis Pharma says India’s CDSCO has cleared its synthetic CBD oral solution (150 mg/mL) for mild-to-moderate anxiety, to be prescribed by psychiatrists and backed by Phase III/IV plans. Medical Cannabis Reality Check: A JAMA review says medical cannabis may help some people with chronic noncancer pain, insomnia, and anxiety, but the strongest support is limited and often based on small studies. Regulated Market Moves: Guam issued its first recreational cultivation license, with the operator calling it a “surreal” start to a regulated industry. Impaired Driving Focus: Vermont is expanding officer training to spot cannabis-impaired drivers after crash data showed more incidents involving cannabis-only suspected cases. Public Safety & Enforcement: Malaysia’s JPJ reported drug-positive commercial drivers, including THC positives, after inspections tied to an ongoing drug operation. Legal/Local Cannabis Cases: Palau charged a woman after alleged THC gummy distribution at a luncheon led to three elderly women being hospitalized. Travel Warning: Thailand’s updated customs rule warns travelers with cannabis could face major penalties without proper permissions. Business/Brand Tie-Ins: BrewDog and Tilray are running a £1M bar tab promotion during football’s tournament.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
